Skip to main content

Table 3 The clinical performance of the risk assessment tool for 6-year prediction of chronic cardio-metabolic disorders and each of the separate diseases: Tehran Lipid and glucose study

From: External validation of the European risk assessment tool for chronic cardio-metabolic disorders in a Middle Eastern population

 

Chronic cardio-metabolic disorders

T2DM

CKD

CVD

Validation

Developed

Validation

Developed

Validation

Developed

Validation

Developed

Men (N = 1310)

 Number of events at score category

261

166

102

68

173

120

59

37

 Number of high-risk populations

575

286

575

286

575

286

575

286

 Sensitivity, %

63.8

42.9

57.4

40.2

72.7

52.6

79.4

50.7

 Specificity, %

70.9

87

63.3

80.9

67.6

84.7

63

79.9

Women (N = 1960)

 Number of events at score category

646

329

189

85

542

304

49

32

 Number of high-risk populations

992

408

992

408

992

408

992

408

 Sensitivity, %

66.7

35.4

75.3

35.6

66.8

38.7

95.9

65.3

 Specificity, %

70.0

92.3

56.5

81.2

65.6

91.1

53.8

80.3

  1. T2DM: Type 2 diabetes; CKD; chronic kidney disease; CVD: cardiovascular disease
  2. The validation cut-off point: ≥ 25 for men and ≥ 19 for women
  3. The developed cut-off point: ≥ 35 for men and women
  4. The number of urban population of Tehran aged 28–85 year according to the Iranian census 2016: 7,214,301 men and 7,223,540 women
  5. Number at risk in Tehran according to the validation cut-off point: 3,166,583 men and 3,655,996 women
  6. Number at risk in Tehran according to the developed cut-off point: 1,587,146 men and 1,516,943 women